Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
4/14/2026, 12:00:00 AM
On April 14, 2026, the U.S. FDA refused to file partner Replimune's application for RP1 in combination with Opdivo for advanced melanoma due to study design concerns.
Korean Translation
2026년 4월 14일, 미국 FDA가 연구 설계 우려를 이유로 옵디보와 병용하는 리플리뮨의 진행성 흑색종 치료제 RP1 허가 신청 접수를 거부함.
Related Recent Events
Booz Allen Hamilton Holding Corporation (BAH) · Earnings Release
Q4 and full fiscal year 2026 earnings release scheduled. Analysts forecast EPS of $1.33 and revenue of $2.88 billion for the quarter. A 5% price impact based on historical volatility is estimated and scheduled.
5/22/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Other
The 2026 Annual Meeting of Shareholders on 2026-05-21 to be held virtually, scheduled.
5/21/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q1 2026 earnings release on 2026-05-19. Medium importance is estimated as earnings reports for a company of this size typically cause moderate price movement, scheduled.
5/19/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife announced it will release its first quarter 2026 financial results after the market closes on May 6, 2026, with a conference call on May 7, 2026, scheduled
5/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q1 2026 earnings results release after market close scheduled.
5/5/2026, 12:00:00 AM
Williams Cos Inc. (The) (WMB) · Earnings Release
Williams plans to announce its first-quarter 2026 financial results after the market closes on Monday, May 4, 2026.. Medium importance justified by typical earnings-related price volatility of 5% or more, scheduled.
5/4/2026, 12:00:00 AM